All Outputs (4)

The MRI central vein marker: differentiating PPMS from RRMS and ischaemic SVD (2018)
Journal Article
Samaraweera, A. P., Falah, Y., Pitot, A., Dineen, R. A., Morgan, P. S., & Evangelou, N. (2018). The MRI central vein marker: differentiating PPMS from RRMS and ischaemic SVD. Neurology, Neuroimmunology and Neuroinflammation, 5(6), Article e496. https://doi.org/10.1212/NXI.0000000000000496

© 2018 The Author(s). Objective To determine whether the assessment of brain white matter lesion (WML) central veins differentiate patients with primary progressive MS (PPMS) from relapsing-remitting MS (RRMS) and ischemic small vessel disease (SVD)... Read More about The MRI central vein marker: differentiating PPMS from RRMS and ischaemic SVD.

Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial (2018)
Journal Article
Varlet, P., Mackay, A., Burford, A., Molinari, V., Jones, D. T., Izquierdo, E., …Jones, C. (2018). Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. Cancer Cell, 33(5), 829-842.e5. https://doi.org/10.1016/j.ccell.2018.04.004

The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between the ages of 3 and 18 years.... Read More about Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.

Characterisation of insulin analogues therapeutically available to patients (2018)
Journal Article
Adams, G. G., Meal, A., Morgan, P. S., Alzahrani, Q. E., Zobel, H., Lithgo, R., …Chayen, N. (2018). Characterisation of insulin analogues therapeutically available to patients. PLoS ONE, 13(3), Article e0195010. https://doi.org/10.1371/journal.pone.0195010

The structure and function of clinical dosage insulin and its analogues were assessed. This included ‘native insulins’ (human recombinant, bovine, porcine), ‘fast-acting analogues’ (aspart, glulisine, lispro) and ‘slow-acting analogues’ (glargine, de... Read More about Characterisation of insulin analogues therapeutically available to patients.

Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma (2018)
Journal Article
Grill, J., Massimino, M., Bouffet, E., Azizi, A. A., McCowage, G., Cañete, A., …Giangaspero, F. (2018). Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma. Journal of Clinical Oncology, 36(10), https://doi.org/10.1200/JCO.2017.76.0611

Purpose Bevacizumab (BEV) is approved in more than 60 countries for use in adults with recurrent glioblastoma. We evaluated the addition of BEV to radiotherapy plus temozolomide (RT+TMZ) in pediatric patients with newly diagnosed high-grade glioma (... Read More about Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma.